Harnessing the therapeutic potential of glucagon-like peptide-1: A critical review

Treatments in Endocrinology

Volumn 1, Issue 2, 2002, Pages 117-125

  Baggio, Laurie L ^a   Drucker, Daniel J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; ISOLEUCINE THIAZOLIDIDE; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROGLUCAGON; REPAGLINIDE; SULFONYLUREA; UNCLASSIFIED DRUG;

APPETITE; ENDOCRINE CELL; GASTROINTESTINAL MOTILITY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0037669726     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201020-00005     Document Type: Review

References (136)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21 (9): 1414-31
2. Zhang BB, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 2000; 4 (4): 461-7
3. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414 (6865): 821-7
4. Dupre J. Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37 (5): 826-8
5. Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide: its physiologic release and insulinotropic action in the dog. Diabetes 1975; 24 (12): 1050-6
6. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28: 704-7
7. Kreymann B, Ghatei MA, Williams G, et al. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 11: 1300-4
8. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-9
9. Creutzfeldt W. The incretin concept today. Diabetologia 1979: 16 (2): 75-85
10. Fehmann H-C, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr Rev 1995; 16: 390-410
11. Goke R, Wagner B, Fehmann HC, et al. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl) 1993; 193 (2): 97-103
12. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994; 51 (1): 63-74
13. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7
14. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20 (6): 876-913
15. Drucker DJ. The glucagon-like peptides. Diabetes 1998; 47: 159-69
16. Holst JJ, Orskov C, Nielsen OV, et al. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-74
17. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987; 84: 3434-8
18. Fehmann H-C, Habener JF. Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma bTC-1 cells. Endocrinology 1992; 130: 159-66
19. Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 1996; 2: 1254-8
20. Kolligs F, Fehmann H-C, Goke R, et al. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44: 16-9
21. Schirra J, Sturm K, Leicht P, et al. Exendin (9-39)amide is an antagonist of glucagon-like peptide-1 (7-36)amide in humans. J Clin Invest 1998; 101 (7): 1421-30
22. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999: 48 (1): 86-93
23. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993; 361: 362-5
24. Byrne MM, Gliem K, Wank U, et al. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 1998; 47 (8): 1259-65
25. Dachicourt N, Serradas P, Bailbe D, et al. Glucagon-like peptide-1 (7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies. J Endocrinol 1997; 155 (2): 369-76
26. Fridolf T, Bottcher G, Sundler F, et al. GLP-1 and GLP-1 (7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 1991; 6 (2): 208-15
27. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-13
28. Suzuki S, Kawai K, Ohashi S, et al. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 1989; 125 (6): 3109-14
29. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagon-like peptide 1-(7-36)-amide. Diabetes 1989; 38: 902-5
30. Matsuyama T, Komatsu R, Namba M, et al. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Diabetes Res Clin Pract 1988; 5 (4): 281-4
31. Vilsboll T, Krarup T, Madsbad S, et al. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 2001; 18 (2): 144-9
32. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-8
33. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73
34. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in type 2 (non-insulin dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-32
35. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103
36. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277 (3 Pt2): R910-6
37. Shimizu I, Hirota M, Ohboshi C, et al. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987; 121: 1076-82
38. Uttenthal LO, Toledano A, Blazquez E. Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 1992; 21: 143-6
39. Larsen PJ, Tang-Christensen M, Holst JJ, et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-70
40. Shughrue PJ, Lane MV, Merchenthaler I. Glucagon-like peptide-1 receptor (GLP-R) mRNA in the rat hypothalamus. Endocrinology 1996; 137: 5159-62
41. Navarro M, Rodriguez de Fonseca F, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996; 67: 1982-91
42. Alvarez E, Roncero I, Chowen JA, et al. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 1996; 66: 920-7
43. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403 (2): 261-80
44. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72
45. Tang-Christensen M, Larsen PJ, et al. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-56
46. Donahey JCK, Van Dijk G, Woods SC. et al. Intraventricular GLP-1 reduces short but not long-term food intake or body weight in lean and obese rats. Brain Res 1998; 779: 75-83
47. Meeran K, O'Shea D, Edwards CM, et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140 (1): 244-50
48. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 1998; 274: R23-9
49. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-20
50. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276 (5 Pt 2): R1541-4
51. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22 (7): 1137-43
52. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23 (3): 304-11
53. D'Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide 1. Diabetes 1995; 44: 1433-7
54. Valverde I, Villanueva-Penacarrillo ML. In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat. Acta Physiol Scand 1996; 157 (3): 359-60
55. Miki H, Namba M, Nishimura T, et al. Glucagon-like peptide-1 (7-36) amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim Biophys Acta 1996; 1312: 132-6
56. Morales M, Lopez-Delgado MI, Alcantara A, et al. Preserved GLP-1 effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997; 46: 1264-9
57. Blackmore PF, Mojsov S, Exton JH, et al. Absence of insulinotropic glucagon-like peptide-1 (7-37) receptors on isolated rat liver hepatocytes. FEBS Lett 1991; 283: 7-10
58. Valverde I, Merida E, Delgado E, et al. Presence and characterization of glucagon-like peptide-1 (7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 1993; 132: 75-9
59. Wheeler MB, Lu M, Dillon JS, et al. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 1993; 133: 57-62
60. Campos RV. Zhang L, Drucker DJ. Differential expression of RNA transcripts encoding unique carboxy-terminal sequences of human parathyroid-related peptide. Mol Endocrinol 1994; 9: 1656-66
61. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 1996; 137: 2968-78
62. Sandhu H, Wiesenthal SR, MacDonald PE, et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 1999; 48 (5): 1045-53
63. Orskov L, Holst JJ, Moller J, et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1996; 39: 1227-32
64. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-8
65. Vella A, Shah P, Basu R, et al. Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000; 49 (4): 611-7
66. Burcelin R, Da Costa A, Drucker D, et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50 (8): 1720-8
67. Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?.). Endocrinology 1999; 140 (2): 778-83
68. Susini S, Roche E, Prentki M, et al. Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta (INS-1) cells. FASEB J 1998; 12 (12): 1173-82
69. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42 (7): 856-64
70. Buteau J, Foisy S, Rhodes CJ, et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001; 50 (10): 2237-43
71. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48 (12): 2358-66
72. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-96
73. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48 (12): 2270-6
74. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 2000; 49: 741-8
75. Perfetti R, Zhou J, Doyle ME, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141 (12): 4600-5
76. Tourrel C, Bailbe D, Meile M-J, et al. Glucagon-like peptide-1 and exendin-4 stimulates b-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50: 1562-70
77. Ling Z, Wu D, Zambre Y, et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 2001; 438 (4): 382-7
78. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-4
79. Rachman J, Gribble FM, Barrow BA, et al. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 1996; 45: 1524-30
80. Rachman J, Barrow BA, Levy JC, et al. Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1 in subjects with NIDDM. Diabetologia 1997; 40: 205-11
81. Gutniak MK, Linde B, Holst JJ, et al. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994; 17: 1039-44
82. Todd JF, Wilding JP, Edwards CM, et al. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27: 533-6
83. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326 (20): 1316-22
84. Dupre J, Behme MT, Hramiak IM, et al. Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 44: 626-30
85. Dupre J, Behme MT, Hramiak IM, et al. Subcutaneous glucagon-like peptide 1 combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care 1997; 20: 381-4
86. Zander M, Taskiran M, Toft-Nielsen MB, et al. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24 (4): 720-5
87. Nauck MA, Sauerwald A, Ritzel R, et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21 (11): 1925-31
88. Larsen J, Hylleberg B, Ng K, et al. Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment. Diabetes Care 2001; 24 (8): 1416-21
89. Zander M, Madsbad S, Madsen JL. Effect of 6-week course of glucagen-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 Mar 9; 359 (9309): 824-30
90. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52
91. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001; 86 (8): 3853-60
92. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86 (8): 3717-23
93. Vaag AA, Holst JJ, Volund A, et al. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996; 135 (4): 425-32
94. Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-96
95. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35
96. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85 (1): 9-24
97. De Meester I, Korom S, Van Damme J, et al. CD26, let it cut or cut it down. Immunol Today 1999; 20 (8): 367-75
98. Pauly RP, Rosche F, Wermann M, et al. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: a novel kinetic approach. J Biol Chem 1996; 271 (38): 23222-9
99. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proe Natl Acad Sci U S A 2000; 97 (12): 6874-9
100. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-7
101. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998; 19 (5): 877-82
102. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 11 diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-31
103. Hansen L, Deacon CF, Orskov C, et al. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140 (11): 5356-63
104. Ritzel U, Leonhardt U, Ottleben M, et al. A synthetic glucagon-like peptide-1 analog with improved plasma stability. J Endocrinol 1998; 159 (1): 93-102
105. Deacon CF, Knudsen LB, Madsen K, et al. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41: 271-8
106. Burcelin R, Dolci W, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 1999; 48 (2): 252-8
107. Xiao Q, Giguere J, Parisien M, et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001; 40 (9): 2860-9
108. Siegel EG, Gallwitz B, Scharf G, et al. Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept 1999; 79 (2-3): 93-102
109. O'Harte FP, Mooney MH, Lawlor A, et al. N-terminally modified glucagon-like peptide-1 (7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 2000; 1474 (1): 13-22
110. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43 (9): 1664-9
111. Larsen PJ, Fledelius C, Knudsen LB, et al. Systemic administration of the longacting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50 (11): 2530-9
112. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem 1992; 267: 7402-5
113. Goke R, Fehmann H-C, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1(7-36)-amide receptor of insulin-secreting b-cells. J Biol Chem 1993; 268: 19650-5
114. Thorens B, Porret A, BŸhler L, et al. Cloning and functional expression of the human islet GLP-1 receptor: Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678-82
115. Schepp W, Schmidtler J, Riedel T, et al. Exendin-4 and exendin-(9-39)NH2: Agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2. Eur J Pharmacol Mol Pharmacol 1994; 269: 183-91
116. Fehmann HC, Jiang J, Schweinfurth J, et al. Stable expression of the rat GLP-1 receptor in CHO cells: activation and binding characteristics utilizing GLP-I 1 (7-36)-amide, oxyntomodulin, exendin-4, and exendin (9-39). Peptides 1994; 15: 453-6
117. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281 (1): E155-61
118. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48 (5): 1026-34
119. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141 (6): 1936-41
120. Al-Barazanji KA, Arch JR, Buckingham RE, et al. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 2000; 8 (4): 317-23
121. Greig NH, Holloway HW, De Ore KA, et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999; 42 (1): 45-50
122. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-70
123. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47 (5): 764-9
124. Pauly RP, Demuth HU, Rosche F, et al. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor I1e-thiazolidide. Metabolism 1999; 48 (3): 385-9
125. Pederson RA, White HA, Schlenzig D, et al. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47 (8): 1253-8
126. Balkan B, Kwasnik L, Miserendino R, et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42 (11): 1324-31
127. Ahren B, Holst JJ, Martensson H, et al. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000: 404 (1-2): 239-45
128. Morimoto, C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998; 166: 55-70
129. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994; 15 (4): 180-4
130. Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 2001; 276 (41): 37787-93
131. Nauck MA, Holst JJ, Willms B, et al. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997; 105 (4): 187-95
132. Ranganath LR, Beety JM, Morgan LM, et al. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916-9
133. Gutniak MK, Larsson H, Sanders SW, et al. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 1997; 20: 1874-9
134. Joseph JW, Kalitsky J, St-Pierre S, et al. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycemia in diabetic db/db mice. Diabetologia 2000; 43 (10): 1319-28
135. Burcelin R, Rolland E, Dolci W, et al. Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N Y Acad Sci 1999; 875: 277-85
136. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15 (4): 297-303